Literature DB >> 32644119

Sociodemographic, Ecological, and Spatiotemporal Factors Associated with Human Immunodeficiency Virus Drug Resistance in Florida: A Retrospective Analysis.

Shannan N Rich1,2, Karalee Poschman3,4, Hui Hu1, Carla Mavian2,5, Robert L Cook1,2, Marco Salemi2,5, Emma C Spencer3, Mattia Prosperi1.   

Abstract

BACKGROUND: Persons living with human immunodeficiency virus (HIV) with resistance to antiretroviral therapy are vulnerable to adverse HIV-related health outcomes and can contribute to transmission of HIV drug resistance (HIVDR) when nonvirally suppressed. The degree to which HIVDR contributes to disease burden in Florida-the US state with the highest HIV incidence- is unknown.
METHODS: We explored sociodemographic, ecological, and spatiotemporal associations of HIVDR. HIV-1 sequences (n = 34 447) collected during 2012-2017 were obtained from the Florida Department of Health. HIVDR was categorized by resistance class, including resistance to nucleoside reverse-transcriptase , nonnucleoside reverse-transcriptase , protease , and integrase inhibitors. Multidrug resistance and transmitted drug resistance were also evaluated. Multivariable fixed-effects logistic regression models were fitted to associate individual- and county-level sociodemographic and ecological health indicators with HIVDR.
RESULTS: The HIVDR prevalence was 19.2% (nucleoside reverse-transcriptase inhibitor resistance), 29.7% (nonnucleoside reverse-transcriptase inhibitor resistance), 6.6% (protease inhibitor resistance), 23.5% (transmitted drug resistance), 13.2% (multidrug resistance), and 8.2% (integrase strand transfer inhibitor resistance), with significant variation by Florida county. Individuals who were older, black, or acquired HIV through mother-to-child transmission had significantly higher odds of HIVDR. HIVDR was linked to counties with lower socioeconomic status, higher rates of unemployment, and poor mental health.
CONCLUSIONS: Our findings indicate that HIVDR prevalence is higher in Florida than aggregate North American estimates with significant geographic and socioecological heterogeneity.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antiretroviral therapy; HIV drug resistance; HIV in the South

Mesh:

Substances:

Year:  2021        PMID: 32644119      PMCID: PMC7938178          DOI: 10.1093/infdis/jiaa413

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Retention in HIV Care and Viral Suppression: Individual- and Neighborhood-Level Predictors of Racial/Ethnic Differences, Florida, 2015.

Authors:  Diana M Sheehan; Kristopher P Fennie; Daniel E Mauck; Lorene M Maddox; Spencer Lieb; Mary Jo Trepka
Journal:  AIDS Patient Care STDS       Date:  2017-04       Impact factor: 5.078

2.  Rural AIDS diagnoses in Florida: changing demographics and factors associated with survival.

Authors:  Mary Jo Trepka; Theophile Niyonsenga; Lorene M Maddox; Spencer Lieb
Journal:  J Rural Health       Date:  2013-01-14       Impact factor: 4.333

3.  Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

Authors:  Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman
Journal:  Clin Infect Dis       Date:  2015-02-13       Impact factor: 9.079

4.  Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Authors:  Roos E Barth; Susan C Aitken; Hugo Tempelman; Sibyl P Geelen; Erik M van Bussel; Andy I M Hoepelman; Rob Schuurman; Annemarie M J Wensing
Journal:  Antivir Ther       Date:  2011-12-02

5.  COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.

Authors:  Daniel Struck; Glenn Lawyer; Anne-Marie Ternes; Jean-Claude Schmit; Danielle Perez Bercoff
Journal:  Nucleic Acids Res       Date:  2014-08-12       Impact factor: 16.971

6.  Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.

Authors:  Andrew N Phillips; John Stover; Valentina Cambiano; Fumiyo Nakagawa; Michael R Jordan; Deenan Pillay; Meg Doherty; Paul Revill; Silvia Bertagnolio
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

7.  The global burden of HIV-1 drug resistance in the past 20 years.

Authors:  Maurizio Zazzi; Hui Hu; Mattia Prosperi
Journal:  PeerJ       Date:  2018-05-25       Impact factor: 2.984

8.  Prevalence and Transmission Dynamics of HIV-1 Transmitted Drug Resistance in a Southeastern Cohort.

Authors:  Sara N Levintow; Nwora Lance Okeke; Stephane Hué; Laura Mkumba; Arti Virkud; Sonia Napravnik; Joseph Sebastian; William C Miller; Joseph J Eron; Ann M Dennis
Journal:  Open Forum Infect Dis       Date:  2018-07-20       Impact factor: 3.835

9.  Baseline differences in characteristics and risk behaviors among people who inject drugs by syringe exchange program modality: an analysis of the Miami IDEA syringe exchange.

Authors:  Siddharth Iyengar; Adam Kravietz; Tyler S Bartholomew; David Forrest; Hansel E Tookes
Journal:  Harm Reduct J       Date:  2019-01-23

Review 10.  HIV-1 drug resistance and resistance testing.

Authors:  Dana S Clutter; Michael R Jordan; Silvia Bertagnolio; Robert W Shafer
Journal:  Infect Genet Evol       Date:  2016-08-29       Impact factor: 3.342

View more
  3 in total

1.  Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA.

Authors:  Vlad Novitsky; Jon Steingrimsson; Fizza S Gillani; Mark Howison; Su Aung; Matthew Solomon; Cindy Y Won; Amy Brotherton; Rajeev Shah; Casey Dunn; John Fulton; Thomas Bertrand; Anna Civitarese; Katharine Howe; Theodore Marak; Philip Chan; Utpala Bandy; Nicole Alexander-Scott; Joseph Hogan; Rami Kantor
Journal:  Open Forum Infect Dis       Date:  2021-12-07       Impact factor: 4.423

2.  Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.

Authors:  Davide F Bavaro; Andrea De Vito; Giuseppe Pasculli; Yagai Bouba; Laura Magnasco; Rachele Pincino; Francesco Saladini; Rossana Lattanzio; Romina Corsini; Serena Arima; Maurizio Zazzi; Francesca Incardona; Barbara Rossetti; Antonia Bezenchek; Borghi Vanni; Antonio Di Biagio
Journal:  J Med Virol       Date:  2022-04-09       Impact factor: 20.693

3.  Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.

Authors:  Alexander J Bailey; Soo-Yon Rhee; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2021-04-15       Impact factor: 1.723

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.